Aphton Appoints Clinical Trials and Regulatory Affairs Director for North America.Business Editors/Health & Medical Writers MIAMI--(BW HealthWire)--August 30, 2000 Aphton Corporation (Nasdaq:APHT APHT Advance Physical Test ) announced today that William D. Perkins, Ph.D., has joined the company and has been appointed to the new senior position of Director, Clinical Trials and Regulatory Affairs, North America. In this position, Dr. Perkins will focus primarily on directing, managing and expanding Aphton's clinical trials in the US and Canada. His responsibilities will include managing the network of participating clinical research centers in coordination with selected Contract Research Organizations (CRO's) and assisting in the preparation of regulatory filings, meetings with and submissions to the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. . Dr. Perkins will also coordinate with and support Aphton's expanding clinical trials programs outside of North America. A company spokesperson stated, "Aphton's U.S. clinical trials are now accelerating; Bill Perkins is a senior, experienced clinical trials director who will assist us in managing and expediting this growing effort. Most importantly, Dr. Perkins will help to move Aphton's anti-gastrin immunogen through the final late-stage U.S. clinical trials." Dr. Perkins has over 20 years experience in the medical field. During the past 17 years in particular, he has been actively involved in oncology/immunology clinical trials, including directing all phases of clinical trial development, from Phase I through post-marketing approval (Phase IV). Dr. Perkins has been a major contributor to the formulation and writing of both investigational new drug (IND) applications and of new drug application (NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any ) submissions to the FDA. Previous senior professional responsibilities in clinical trials and medical affairs include affiliations with ILEX Ilex a bush bearing berries containing saponins; cause vomiting, diarrhea. Called also holly. Oncology (Nasdaq:ILXO), Elan Corporation PLC (NYSE NYSE See: New York Stock Exchange :ELN Noun 1. ELN - a Marxist terrorist group formed in 1963 by Colombian intellectuals who were inspired by the Cuban Revolution; responsible for a campaign of mass kidnappings and resistance to the government's efforts to stop the drug trade; "ELN kidnappers target ) and Novartis (NYSE:NVS NVS - Non-Volatile Storage ). Aphton Corporation is a biopharmaceutical company developing products using its innovative vaccine-like technology for neutralizing hormones that participate in gastrointestinal system and reproductive system cancer and non-cancer diseases; and the prevention of pregnancy. Aphton has strategic alliances with Aventis Pasteur (NYSE:AVE), SmithKline Beecham PLC (NYSE:SBH SBH State Bank of Hyderabad (India) SBH Small Business Hawaii (non-profit business advocacy organization) SBH Sequencing By Hybridization SBH St Barthelemy, Guadeloupe (Airport Code) ), Schering Plough Animal Health (NYSE:SGP) and the World Health Organization (WHO). Except for the historical information herein, the matters discussed herein include forward-looking statements that may involve a number of risks and uncertainties. Future results may vary insignificantly based on a number of factors including, but not limited to, intellectual property risks, risks in regulatory and market acceptance of new products and continuing demand for same, the impact of competitive products and pricing, changing economic conditions and other risk factors detailed in Aphton's most recent 10-K and other filings with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion